ライフサイエンスコーパス: neck cancer

1 peripheral blood from patients with head and neck cancer.

2 (LR) and distant metastases (DM) in head-and-neck cancer.

3 non-small-cell lung cancer, and in head and neck cancer.

4 nary management of various types of head and neck cancer.

5 nts with traditional, HPV-negative, head and neck cancer.

6 om neck dissection in patients with head and neck cancer.

7 apy resistance in HA/CD44-activated head and neck cancer.

8 tric cancer, urothelial cancer, and head and neck cancer.

9 ard the betterment of patients with head and neck cancer.

10 dity and mortality in patients with head and neck cancer.

11 (HNSCC) is the most common form of head and neck cancer.

12 for viral mediated gene therapy of head and neck cancer.

13 effects associated with therapy for head and neck cancer.

14 data of 1,019 patients with lung or head-and-neck cancer.

15 phenotype existing in both lung and head-and-neck cancer.

16 ificant treatment for patients with head and neck cancer.

17 hotosensitizer for PDT of resistant head and neck cancer.

18 tic relevance of targeting CXCR7 in head and neck cancer.

19 y or combined chemoradiotherapy for head and neck cancer.

20 r than lung, such as pancreatic and head and neck cancer.

21 ith lymphoma, colorectal cancer, or head and neck cancer.

22 st time high expression of CXCR7 in head and neck cancer.

23 ns, putting them at higher risk for head and neck cancer.

24 mented for recurrent and metastatic head and neck cancer.

25 ncluding sarcoma, glioblastoma, and head and neck cancer.

26 ther female genital; leukaemia; and head and neck cancer.

27 ng over 90% of patients treated for head and neck cancer.

28 after radiotherapy in patients with head and neck cancer.

29 mmon consequence of radiotherapy in head and neck cancer.

30 those treated with irradiation for head and neck cancer.

31 CT) images to classify lung, colon, head and neck cancer.

32 s to the tumor in a murine model of head and neck cancer.

33 icity of radiation therapy (RT) for head and neck cancer.

34 (HNSCC) accounts for nearly 90% of head and neck cancer.

35 r cervical cancer and oropharyngeal head and neck cancer.

36 ((18)F-FMISO) dynamic PET (dPET) in head and neck cancer.

37 nd patient outcomes in cervical and head and neck cancers.

38 in T-cell-inflamed tumor models of head and neck cancers.

39 as anticancer therapy for advanced head and neck cancers.

40 biomarkers for cervical as well as head and neck cancers.

41 rs constitute a unique entity among head and neck cancers.

42 ntion and treatment of HPV-positive head and neck cancers.

43 man cancers, including cervical and head-and-neck cancers.

44 ia radiosensitizer for treatment of head and neck cancers.

45 ther validated in another cohort of head and neck cancers.

46 ers, including cervical cancer, and head and neck cancers.

47 ple cancers, including cervical and head-and-neck cancers.

48 nt toxicity during radiotherapy for head and neck cancers.

49 esponse assessment using PET/CT for head and neck cancers.

50 vulvar, vaginal, penile, anal, and head-and-neck cancers.

51 d many other tumors, including many head and neck cancers.

52 he clinical workup of patients with head and neck cancers.

53 of lung (stage I), bladder, kidney, and head/neck cancers.

54 in patients with breast, lung, and head and neck cancers.

55 y associated with increased risk of head and neck cancers.

56 ing side effect of radiotherapy for head and neck cancers.

57 positioning in radiation therapy of head and neck cancers.

58 well as a subset of anogenital and head and neck cancers.

59 ons to 71 patients with stages I-IV head and neck cancers.

60 s of carcinogenesis in cervical and head and neck cancers.

61 globally and is a leading cause of head and neck cancers.

62 frequently overexpressed in oral, head, and neck cancers.

63 alignancies, including cervical and head and neck cancers.

64 cinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenoc

65 ncer, 28.6 versus 35.5 versus 39.4; head and neck cancer, 21.1 versus 29.4 versus 40.2; and breast ca

66 o 46.4%), followed by patients with head and neck cancer (40.8%; 95% CI, 28.5% to 53.0%).

67 In head and neck cancer, a change in (18)F-FLT uptake early during r

68 ition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves re

69 HPV-negative head and neck cancers abundantly express EGFR, and the monoclonal

70 on-small cell lung, esophageal, and head and neck cancer, among others, are intrinsically resistant t

71 e routinely obtained in the care of head and neck cancer and are clearly associated with patient outc

72 e routinely obtained in the care of head and neck cancer and are clearly associated with patient outc

73 ty as well as invasive potential in head and neck cancer and breast cancer cells.

74 the early response to treatment of head and neck cancer and evaluated the association between PET pa

75 ch is common after radiotherapy for head and neck cancer and for which no effective treatments are av

76 stay of treatment for patients with head and neck cancer and has traditionally involved a stage-depen

77 reported the somatic alterations in head and neck cancer and have highlighted the distinct genetic an

78 mon side effect of radiotherapy for head and neck cancer and is difficult to remedy.

79 s carrying BRCA mutations: one with head and neck cancer and one with ovarian cancer.

80 "oral clocks" and diseases such as head and neck cancer and Sjogren's syndrome.

81 diation resistance in patients with head and neck cancer and summarizes how cancer cells evade radiat

82 potential prognostic biomarker for head and neck cancer and that MK2 pathway activation can mediate

83 vity of HPV and driver mutations in head-and-neck cancer and the association of HPV with APOBEC mutat

84 ese two genes, Ubiquitin C (UBC) in head and neck cancer and Transferrin receptor (TFRC) and beta-Glu

85 d therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are

86 biology of recurrent and metastatic head and neck cancers and review implementation of precision onco

87 biology of recurrent and metastatic head and neck cancers and review implementation of precision onco

88 st were detectable in lung cancers, head and neck cancers and tumors from patients exposed to SN2-typ

89 t in the diagnosis and treatment of head and neck cancer, and building surgical capacity, which offer

90 g locally advanced cervical cancer, head and neck cancer, and lung cancer.

91 umours including gliomas, sarcomas, head and neck cancers, and carcinosarcomas.

92 man cancers, including cervical and head and neck cancers, and is responsible for the annual deaths o

93 ng overweight before diagnosis with head and neck cancer are associated with a better prognosis.

94 t effects of smoking and alcohol in head and neck cancer are not clear, given the strong association

95 Head and neck cancers are a heterogeneous collection of malignanc

96 Most head and neck cancers are derived from the mucosal epithelium in

97 and pathogenesis of HPV-associated head-and-neck cancers as well as current treatment modalities for

98 es discussed in this Review include head and neck cancer, breast cancer, sarcoma, gastrointestinal ca

99 can not only address the burden of head and neck cancer, but also create a platform for beginning to

100 s have elucidated relevant genes in head and neck cancer, but HPV-related tumors have consistently sh

101 eported in HPV-related cervical and head and neck cancers, but such data have not been available for

102 r APOBEC3B upregulation in cervical and head/neck cancers, but the mechanisms underlying nonviral mal

103 diation in resistant and aggressive head and neck cancer by 100-fold in vitro and 17-fold in vivo, re

104 o image unlabeled glucose uptake in head and neck cancer by using a clinical 3T magnetic resonance im

105 reatment for patients with advanced head and neck cancer can be associated with many side-effects, an

106 e conclude that glucoCEST images of head and neck cancer can be obtained with a clinical 3T MRI scann

107 Radiation therapy for head and neck cancer can result in extensive damage to normal adj

108 d with outcome when considering all head and neck cancer cases (HR for serology,0.49; 95% CI, 0.23-1.

109 sensitivity of the cisplatin-resistant head-neck cancer cell line Cal27CisR by almost 7-fold.

110 We also show that head and neck cancer cell lines with loss-of-function mutations i

111 tinct between high and low invasive head and neck cancer cells and between CSCs and non-SCCs.

112 untargeted metabolomic analysis of head and neck cancer cells and stem-like cancer cells.

113 analysis of targeted metabolites in head and neck cancer cells as well as cancer stem-like cells (CSC

114 killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a

115 PNBs were generated in vivo in head and neck cancer cells by systemically targeting tumours with

116 versely, whereas p53 wild-type HN30 head and neck cancer cells did show sensitization to radiation up

117 vidence that Hpa2 overexpression in head and neck cancer cells markedly reduces tumor growth.

118 we show that cisplatin treatment of head and neck cancer cells results in nuclear transport of p16 le

119 psilon led to increased survival of head and neck cancer cells under hypoxia, providing evidence that

120 le toxicity and biocompatibility in head and neck cancer cells.

121 protein kinase (AMPK) signaling in head and neck cancer cells.

122 s, but did not accelerate growth of head and neck cancer cells.

123 T) is a promising approach to treat head and neck cancer cells.

124 ted with EGFR surface expression in head and neck cancer cells.

125 med RNA-Seq of normoxic and hypoxic head and neck cancer cells.

126 carcinoma (OSCC) is the most common head and neck cancer characterized by aggressive local invasion a

127 al carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) in

128 the incidence of tobacco-associated head and neck cancers decreased for elderly patients (larynx: APC

129 ors are relatively inefficacious in head and neck cancers, despite an abundance of genetic alteration

130 of human cancer, but their role in head and neck cancer development and progression is not well defi

131 Patients with head and/or neck cancer diagnoses were excluded.

132 (HPV) sequences and that HPV-driven head and neck cancers display distinct biological and clinical fe

133 nimal studies in osteoarthritis and head and neck cancer, early blockade of NGF reduced weight loss i

134 found in subregions of cervical and head and neck cancers, enable HPV-positive cancer cells to escape

135 large database of the International Head and Neck Cancer Epidemiology (INHANCE) Consortium, including

136 ,375 controls) in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium, we applie

137 aled that HPV-positive cervical and head-and-neck cancers exhibited higher rates of hA3 mutation sign

138 tform which maintains precision cut head and neck cancer for the purpose of ex vivo irradiation is de

139 Head and neck cancer, for which the diagnosis and treatment are o

140 ,179 with kidney cancer, and 2,967 with head/neck cancer from five cohort studies.

141 accurate subtype identification in head and neck cancer from gene expression data in both formalin-f

142 th oropharyngeal cancer data from a head and neck cancer genome-wide association study (GWAS).

143 on, replicated significantly in the head and neck cancer GWAS limited to HPV-seropositive cases and a

144 ors in lymphoma, breast cancer, and head and neck cancer has been previously established.

145 hods to reduce SSI in patients with head and neck cancer have been intensely researched, yielding evo

146 interaction with the host genome in head and neck cancers have not been comprehensively described.

147 The most common type of head and neck cancer, head and neck squamous cell carcinoma (HNSC

148 s of stage I lung, bladder, kidney, and head/neck cancers highlight the importance of smoking cessati

149 of cancer, but prospective data on head and neck cancer (HNC) and oesophagus cancer are limited.

150 f CXCL14 expression in HPV-positive head and neck cancer (HNC) cells dramatically suppresses tumor gr

151 tudies on smokeless tobacco use and head and neck cancer (HNC) have found inconsistent and often impr

152 Head and neck cancer (HNC) is the seventh most common cancer worl

153 Head and neck cancer (HNC) is the seventh most-common type of can

154 /radiation therapy (C/RT) to manage head and neck cancer (HNC) patients affects their ability to swal

155 overall survival and HPV status in head and neck cancer (HNC) patients.

156 ing tumor cells (CTCs) in blood for head and neck cancer (HNC) patients.

157 kg)/height (m)2) and survival among head and neck cancer (HNC) patients.

158 guidelines recommend patients with head and neck cancer (HNC) receive treatment at centers with expe

159 Head and neck cancer (HNC) risk prediction models based on risk f

160 s on the management of adults after head and neck cancer (HNC) treatment, focusing on surveillance an

161 (EGFR) is an established target in head-and-neck cancer (HNC), resistance to EGFR-targeted therapy m

162 In patients with head and neck cancer (HNC), the surrounding normal salivary gland

163 er-associated fibroblasts (CAFs) in head and neck cancer (HNC), thereby promoting tumorigenesis via m

164 +) flux on TIL effector function in head and neck cancer (HNC).

165 s types of human cancers, including head and neck cancer (HNC).

166 promising, have variable benefit in head and neck cancer (HNC).

167 various types of cancer, including head and neck cancer (HNC); other strategies involving combinatio

168 ios, and fish with the incidence of head and neck cancer (HNC; n = 2,453), esophageal adenocarcinoma

169 A) for HPV16-positive and -negative head and neck cancers (HNC) suggesting that E2 plays a role in th

170 Many cancer types, including head and neck cancers (HNC), express programmed death ligand 1 (P

171 ical specimens of glioblastomas and head and neck cancers (HNCs) and is required for EGFR-stimulated

172 Head and neck cancers (HNCs) cause significant mortality and morb

173 body cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients,

174 ing HPV-associated and HPV-negative head and neck cancers (HNSCC).

175 The management of patients with head and neck cancer implies a multidisciplinary treatment with s

176 etween use of smokeless tobacco and head and neck cancer in 11 US case-control studies.

177 nagement of locoregionally confined head and neck cancer in elderly patients and propose a practical

178 Head and neck cancer in elderly patients represents a major healt

179 e to the morbidity and mortality of head and neck cancer in India, Pakistan, and Bangladesh for 1 yea

180 ding the morbidity and mortality of head and neck cancer in India, Pakistan, and Bangladesh, along wi

181 In head and neck cancer in particular, proton beam therapy is unique

182 otal economic welfare losses due to head and neck cancer in the aforementioned countries in the year

183 n-based study of 1054 patients with head and neck cancer in the greater Boston, Massachusetts, area (

184 n-based study of 1054 patients with head and neck cancer in the greater Boston, Massachusetts, area (

185 ne derivatives for the treatment of head and neck cancer in the hamster cheek pouch oral cancer model

186 e of economic welfare losses due to head and neck cancer in the three studied countries is US$16.9 bi

187 accuracy of pathologists detecting head and neck cancers in histological images.

188 ndometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leuk

189 The current standard of care for head and neck cancer includes surgical resection of the tumor fol

190 immunological principles related to head and neck cancer, including the concept of cancer immunosurve

191 Primary management for head and neck cancers, including squamous cell carcinoma (SCC), i

192 Among these cancers, HPV-associated head-and-neck cancers, inclusive of oropharyngeal squamous cell c

193 Head and neck cancer is a leading cause of cancer-related mortali

194 Head and neck cancer is becoming more common, and survival rates

195 Head and neck cancer is disfiguring and deadly, and contemporary

196 Head and neck cancer is one of the most prevalent cancers around

197 Head and neck cancer is the fifth most common cancer worldwide.

198 adiotherapy alone for patients with head and neck cancer is unclear.

199 e for predicting patient outcome in head and neck cancer is unknown.

200 and meet the needs of survivors of head and neck cancer is urgently required.

201 Recurrent and/or metastatic head and neck cancer is usually incurable.

202 rtance: Recurrent and/or metastatic head and neck cancer is usually incurable.

203 ents with resected locally advanced head and neck cancer (LAHNC) with negative surgical margins (SM n

204 d trials in locoregionally advanced head and neck cancers (LAHNCs).

205 Epigenetic correlates of the head and neck cancer may illuminate its pathogenic roots.

206 une pathway derangements within the head and neck cancer microenvironment and discuss combination tre

207 to EGFR inhibition in HPV-negative head and neck cancer might help identify novel and active therapi

208 The heterotopic syngeneic murine head and neck cancer model (mEER) caused systemic inflammation an

209 have contributed to discovery of a head and neck cancer mutation association.

210 l nervous system disorder (n = 51), head and neck cancer (n = 47), and other malignancy (n = 51).

211 reast (n = 7), stomach (n = 2), and head and neck cancers (n = 3), as well as unknown primary tumor (

212 though promising, for patients with head and neck cancer need to be demonstrated in prospective rando

213 a multivariable model, having lung/head and neck cancer (odds ratio [OR], 1.74; 95% CI, 1.26-2.41),

214 fect of therapeutic irradiation for head and neck cancer or autoimmune diseases such as Sjogren's syn

215 are-as-usual (CAU) in patients with head and neck cancer or lung cancer who have psychological distre

216 ng distress levels of patients with head and neck cancer or lung cancer.

217 therapeutic radiation treatment for head and neck cancers or from the autoimmune disease Sjogren synd

218 tion of diet and weight status with head and neck cancer outcomes.

219 Head and neck cancers overexpress EGFR and have a high frequency

220 l carcinoma and a growing number of head-and-neck cancers, p53 is degraded by the viral oncoprotein E

221 use was positively associated with head and neck cancer, particularly for cancers of the oral cavity

222 nd their target mRNAs contribute to head and neck cancer pathogenesis and progression.

223 the clinical relevance, a cohort of head and neck cancer patient biopsies was examined for phosphoryl

224 Methods: Head and neck cancer patients (n = 14) scheduled for curative res

225 orrelates with enhanced survival of head and neck cancer patients (p < 0.0000542), indicating the imp

226 n of chemo-radiation treatments for head-and-neck cancer patients from different risk groups.

227 ospectively collected data from 644 head and neck cancer patients including both clinical and radiomi

228 Head and neck cancer patients receiving conventional repeated, lo

229 : Before a prospective cohort of 25 head and neck cancer patients started radiotherapy, they were exa

230 herapy is a promising treatment for head and neck cancer patients that suffer from chronic dry mouth

231 Head and neck cancer patients treated by radiation commonly suffe

232 a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy

233 e severity of oral mucositis in the head and neck cancer patients under RT, but not to the use of glu

234 tatic LNs compared to benign LNs in head and neck cancer patients undergoing an elective neck dissect

235 preserve salivary gland function in head and neck cancer patients undergoing radiotherapy.

236 One hundred twenty head and neck cancer patients underwent 0- to 30-min (18)F-FMISO

237 In head and neck cancer patients, Hpa2 expression was markedly eleva

238 n independent data sets of lung and head-and-neck cancer patients, many of which were not identified

239 significant unmet clinical need for head and neck cancer patients.

240 ility of multiparametric imaging in head and neck cancer patients.

241 l setting and in clinical trials in head and neck cancer patients.

242 ating GRIM-19 mutations in a set of head and neck cancer patients.

243 samples from lung, colorectal, and head and neck cancer patients.

244 rimantadine to improve outcomes for head and neck cancer patients.

245 atic LNs in the ex vivo setting for head and neck cancer patients.

246 reconstruction on flap outcomes in head and neck cancer patients.

247 agement of this severe morbidity in head and neck cancer patients.

248 fied 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx

249 Head and neck cancers positive for human papillomavirus (HPV) are

250 Head and neck cancers positive for human papillomavirus (HPV) hav

251 ied causative agent for a subset of head and neck cancers, primarily in the oropharynx, and is largel

252 d weight status are associated with head and neck cancer prognosis.

253 s as etiological agents in oral and head and neck cancer prompted the development of new diagnostic a

254 t genetic correlations between lung and head/neck cancer (r(g) = 0.57, p = 4.6 x 10(-8)), breast and

255 rrelates with prostate, breast, and head and neck cancer recurrence.

256 8)F-FDG PET in assessment of PNS in head and neck cancer remains to be explored, in contrast to MRI a

257 (up to 30%) of positive margins in head and neck cancer resections.

258 Radiation therapy for head and neck cancers results in permanent damage to the saliva p

259 Head and neck cancer risk was elevated for those who reported exc

260 mproved patient survival across all head and neck cancer sites: HR for oropharynx cancer, 0.26; 95% C

261 nnaire-Core 30 (QLQ-C30), the EORTC head and neck cancer-specific module (EORTC QLQ-H&N35), and the t

262 estingly, HPV-positive cervical and head-and-neck cancer specimens were recently shown to harbor sign

263 frequently reported in cervical and head and neck cancer specimens.

264 of collectively invading breast and head and neck cancer spheroids, here we identify hypoxia, a hallm

265 ed by sphere formation of colon and head and neck cancer stem cells under nonadherent conditions.

266 hich are distinct from HPV-negative head and neck cancers, suggesting that virus-associated tumors co

267 Head and neck cancer surgery is often a complex multi-step proced

268 ds with 40 international experts in head and neck cancer surgical, radiation, and medical oncology, r

269 As the population of head and neck cancer survivors increases, it has become increasin

270 cers, Study of Exome Sequencing for Head and Neck Cancer Susceptibility Genes, Genetic Epidemiology o

271 HPV16 life cycle and HPV16-positive head and neck cancers (the majority of which retain E2 expression

272 te, breast, colorectal, esophageal, and head/neck cancers, the survival benefit associated with marri

273 Herein, we review late effects of head and neck cancer therapy, highlighting recent advances.

274 portant role in chemosensitivity of head and neck cancers through ubiquitination of NFkappaB.

275 ossible biomarker of sensitivity of head and neck cancers to cell killing after PDT.

276 cancer, cervical cancer, and HPV(+) head and neck cancer tumors.

277 the molecular profiles of many rare head and neck cancer types are unknown.

278 d acute toxicities in patients with head and neck cancer undergoing RT.

279 Forty-eight patients with head and neck cancer underwent (18)F-FLT PET/CT before and during

280 for primary staging or restaging of head and neck cancer underwent sequential whole-body (18)F-FDG PE

281 back as 3000 BCE show that oral and head and neck cancer was a disease process well known to Egyptian

282 In clinical specimens of head and neck cancer, we found that coamplification of BMI1 and A

283 atments for patients with recurrent head and neck cancer, we reviewed the evidence on commonly used p

284 ed, non-metastatic, newly diagnosed head and neck cancer were eligible.

285 o the multistep process of oral and head and neck cancer were made possible by the use of the hamster

286 images (WSI) from 156 patients with head and neck cancer were used to train, validate, and test an in

287 HPV-positive head and neck cancers were more heavily infiltrated by regulatory

288 for colon, lung, hepatobiliary, and head and neck cancer, which are predominantly diseases of the eld

289 tic use from inhibiting Aurora A in head and neck cancers, which overexpress BMI1.

290 propriately selecting patients with head and neck cancer who can benefit from CTX in combination with

291 f 542 patients with newly diagnosed head and neck cancer who completed food-frequency questionnaires

292 ceptional responder with metastatic head and neck cancer who experienced a complete response to immun

293 tic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth

294 nonsquamous, squamous cell lung or head and neck cancers who were treated with the approved PD1-targ

295 65 public data sets of lung, colon, head and neck cancer with high classification rate.

296 We profiled a cohort of 279 head and neck cancers with next generation RNA and DNA sequencing

297 les from patients with HPV-positive head and neck cancers, with active production of HPV-specific IgG

298 immune escape mechanisms enacted by head and neck cancer within the tumor microenvironment allows for

299 a patient-derived CXCR7-expressing head and neck cancer xenograft model in nude mice, tumor growth w

300 aring MDA-MB-231 breast cancer and FaDu head neck cancer xenografts show different pO(2) responses du